

Support of the European Union to Research on Rare Diseases

Dr Alain Vanvossel

European Commission Research Directorate General Health Directorate - Major Diseases Unit





Rare Diseases: is research needed?

Directorate General for Research = European public research funding body



- · complementation of private sector- funded research
- European added value








Rare Diseases: is research needed?

General objectives of FP - Health:



Specific objectives of FP:

- improve the prevention and management of important causes of mortality and ill health in Europe,
- pool Europe's research
 resources for tackling (rare)
 diseases.

Topics mentioned in the work programmes of the calls for proposals





EU historical support to RD research

Previous programmes:

Promote cooperation, collaboration and knowledge building

FP5: Total 45 RD projects, € 62 million

• R&D: Friedreich's Ataxia; Peroxisomal diseases; Myopathies; Congenital disorders of glycosylation; Juvenile systemic lupus erythematosus; Cystic fibrosis

• INFRA: European network of DNA, cell and tissue banks on rare diseases


• Biotech: Gene therapy for inherited diseases; Genechip technology for detection of molecularly heterogeneous genetic diseases





FP6:

Develop scientific and technical excellence



Make a reality of the "European Research Area", with a view to stepping up innovation in Europe, in conjunction with all the efforts made to this end at regional, national and European level.





RD research in FP6

Community Research

INTEGRATING EUROPEAN RESEARCH								
THEMATIC PRIORITIES							SPECIFIC ACTIVITIES COVERING A	
1	2	3	4	5	6	7	WIDER FIELD OF RESEARCH	
and th	nd name were sees and a ment, yster	knowledge-	Supporting EU policies	Anticipating scientific and technological needs				
Life sciences, genomics and biotechnology for health		Nanotechnologies and nanosomintelligent mat., new proderocesses	প্ত	Food quality and safe	development, and ecosysten	Citizens & governance in a kn based society	Horizontal resear	ch activities involving
							Specific measures	
							Non-nuclear activ	vities of the Joint

STRUCTURING THE EUROPEAN RESEARCH AREA (ERA)							
Research	Human	Research infrastruct.	Science				
&	res.,		and				
Innovation	mobility		Society				

STRENGTHENING THE					
FOUNDATIONS OF ERA					
Coordination of activities	Development of research/innovation policies				






Community Research

Objectives of Thematic Priority 1 (overall budget in FP6: € 2255 Million)

Translate genome data into practical applications to improve human health

How will this be achieved?

Necessity to reach a critical mass, management simplification and integration of the research capacities



Introduction of new instruments:
Integrated Projects (IP)
and

Networks of Excellence (NoE)
To complement STREP/CA/SSA





PRIORITY 1: Life Sciences,
Genomics
and Biotechnology for Health

- · Three calls for proposals already published
- · 26 RD relevant projects selected for funding in the 2 first calls, total budget € 93 million
- · Expected global budget for RD: up to € 150 million





"Rare Diseases" - calls overview

1st Call

RD of mitochondria (IP)

RD of plasma membrane transporters for amino-acids (STREP)

Network for early clinical trials in Wilson disease (CA) Coordination of RD research (55A)

Rare hereditary neurological disorders: ataxias (IP)

Rare monogenic neurological disorders (STREP)

2nd Call

Prader-Willi syndrome (STREP)

Rare autoimmune disorders (STREP)

Rare genetic skin disorders (CA)

Disorders of inborn errors of metabolism (CA)

3rd Call

RD of nuclear organisation (STREP)

Pharmacogenomics - orphan medicinal products (STREP)

Cystic fibrosis (CA)

Methodological challenges of early clinical trials in RD (CA or SSA)





! Rare Diseases = necessary keyword to identify relevant topics in the work programme:

e.g. 3rd call:

- Quality and safety standards for clinical gene transfer - NoE.
- Workshop on ethical issues raised by new diagnostic methods - SSA.

Rare diseases can serve as models for other diseases!





Rare Diseases (FG + Biotech)

DNA damage and repair mechanisms in health and disease (IP)

Functional genomics: study of peroxisomes in health and disease (IP)

Low abundance proteomics: cystic fibrosis model (STREP)

Genetic testing in Europe (NoE)

Molecular diagnostics in mitochondrial diseases (STREP)

Retroviral transgenesis in gene therapy of inherited diseases (IP)

Improving precision of nucleic acid-based therapy of cystic fibrosis (STREP)

Gene transfer for curative therapy of human skin disease (STREP)





4th call for proposals Emphasis on SMEs!

<u>Indicative</u> topics? (not published yet; foreseen June 2005)

- protein folding
- ·rare diseases models
- ·bone/cartilage diseases
- ·neuromuscular diseases





Objectives of Priority 8

Underpin the formulation and implementation of Community policies

One action line devoted to Public Health issues, including RD

EURO-POLICY-PID (STREP): Policy-oriented and harmonising research activities in primary immunodeficiency diseases (PIDs)

Objectives of Coordination of Activities

Encourage and support initiatives undertaken by several countries, to develop synergy between their existing activities, as well as to define and implement joint activities, in areas such as health, including the RD area.

E-Rare (55A): ERA-Net for research programmes on RD





Towards FP7

Communication: "Science and technology, the key to Europe's future - Guidelines for future European Union policy to support research" http://europa.eu.int/comm/research/future/index_en.cfm

Open consultation on the future of European research policy



Preparation of the proposal for the 7th FRAMEWORK PROGRAMME (FP7)







Six major objectives:

- 1. Creating European centres of excellence through collaboration between laboratories
- 2. Stimulating the creativity of basic research through competition between teams at European level
- 3. Launching European technological initiatives
- 4. Improving the coordination of national research programmes
- 5. Making Europe more attractive to the best researchers
- 6. Developing research infrastructures of European interest







OTHER:

- Enhance european scientific presence in international setting
- Stimulate research for and by SME
- Encourage technology innovation







Research Themes for FP7? Open consultation on thematic domains for future European support under FP7



Domains where support at European level

- · is most needed
- will have the greatest impact

based on:

- European added value
- Contribution to EU policy objectives
- · European research potential





Indicative roadmap for FP7

- (Decision on Financial Perspectives)
- Commission proposal for FP: towards April 2005
- Commission proposals for Specific Programmes: towards September 2005
- Adoption of FP by European Council and European Parliament: foreseen June 2006
- Adoption of Specific Programmes by the European Council: foreseen September 2006
- · Publication of first calls for proposals: November 2006





Towards FP7

Input

- · Reflexion workshop April 2005 (DG RTD)
- · Received position papers (e.g. EURORDIS)
- · Conferences: ICORD, Lux. RD conference June 2005
- · Your free input!





Cordis website for Priority 1: http://www.cordis.lu/lifescihealth/home.html

Alain. Van-Vossel@cec.eu.int Catherine. Berens@cec.eu.int

